GO:0010745 negative regulation of macrophage derived foam cell differentiation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010745 describes the biological process that suppresses the transformation of macrophages into lipid-laden foam cells, a hallmark of early atherosclerosis.
• Key negative regulators include nuclear receptors such as PPARγ and PPARα, transcription factors like KLF4 and RFX1, and secreted factors such as CNP and omentin-1.
• Dysregulation of this process leads to excessive foam cell formation, promoting atherosclerotic plaque development and cardiovascular disease.
• Experimental models for studying this process include apoE-/- and LDLR-/- mice, primary macrophage cultures, and CRISPR-engineered cell lines.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of genes that negatively regulate foam cell differentiation.
• Understanding this process offers therapeutic targets for atherosclerosis, and modulating key regulators can attenuate lesion formation in preclinical models.
Description
Macrophage derived foam cells are lipid-laden macrophages that accumulate in the arterial wall and are a defining feature of early atherosclerotic lesions. The process of foam cell differentiation is driven by the uptake of modified lipoproteins, such as oxidized low-density lipoprotein (oxLDL), through scavenger receptors like CD36 and SRA. However, this process is not unidirectional; it is subject to negative regulation by a variety of intracellular and extracellular factors that limit lipid accumulation and inflammatory activation. GO:0010745, negative regulation of macrophage derived foam cell differentiation, captures the biological processes that suppress the transition of macrophages into foam cells. This term is of significant interest to researchers studying atherosclerosis, lipid metabolism, and inflammation, as it represents a potential point of therapeutic intervention. Understanding the molecular players and mechanisms that negatively regulate foam cell formation is essential for developing strategies to prevent or treat cardiovascular disease.
negative regulation of macrophage derived foam cell differentiation At A Glance
| GO ID | GO:0010745 |
|---|---|
| GO term | negative regulation of macrophage derived foam cell differentiation |
| Ontology | biological_process |
| Synonym | None |
| Major function | Suppression of the conversion of macrophages into lipid-laden foam cells, a key step in atherosclerosis. |
| Related processes | Cholesterol efflux, inflammatory response, lipid metabolism, scavenger receptor signaling. |
| Key regulators | PPARγ, PPARα, KLF4, RFX1, CNP, omentin-1, NFAT. |
| Disease relevance | Atherosclerosis, cardiovascular disease, metabolic disorders. |
What Is GO:0010745?
GO:0010745 is a biological process term that refers to any process that stops, prevents, or reduces the rate or extent of macrophage derived foam cell differentiation. In other words, it encompasses the cellular and molecular events that inhibit the conversion of macrophages into foam cells, which are characterized by the accumulation of cholesterol esters and other lipids. This negative regulation can occur through various mechanisms, including the suppression of scavenger receptor expression, enhancement of cholesterol efflux, or modulation of inflammatory signaling pathways that promote lipid uptake.
Why Is negative regulation of macrophage derived foam cell differentiation Important in Cell Biology?
The negative regulation of macrophage derived foam cell differentiation is critically important because foam cell formation is a central event in the initiation and progression of atherosclerosis. Uncontrolled foam cell formation leads to the development of fatty streaks, which can progress to complex plaques, causing myocardial infarction and stroke. Therefore, understanding the mechanisms that negatively regulate this process can reveal therapeutic targets to halt or reverse atherosclerosis. Moreover, this process intersects with broader aspects of macrophage biology, including inflammation, lipid handling, and immune regulation, making it relevant to a wide range of diseases beyond cardiovascular disease.
• Foam cell formation is a hallmark of early atherosclerosis, and its negative regulation can prevent plaque development.
• Key negative regulators such as PPARγ and PPARα are targets of existing drugs (e.g., thiazolidinediones, fibrates) used for metabolic disorders.
• The process is modulated by inflammatory signaling pathways, linking it to chronic inflammatory diseases.
• Genetic variations in negative regulators like KLF4 and RFX1 are associated with altered atherosclerosis risk.
• Studying this process provides insights into macrophage lipid metabolism and cholesterol homeostasis.
• It offers potential for developing novel therapeutics that promote cholesterol efflux and reduce inflammation.
• Modeling this process in vitro and in vivo is essential for preclinical drug testing.
• CRISPR-based gene editing enables precise dissection of causal genes in this pathway.
• The process is conserved across species, allowing translation from mouse models to humans.
• Understanding it may also impact other diseases such as obesity, diabetes, and neurodegenerative disorders.
What Happens During negative regulation of macrophage derived foam cell differentiation?
Inhibition of Scavenger Receptor-Mediated Lipid Uptake
In simple terms: This step blocks the doors that let bad cholesterol into macrophages.
Macrophages take up modified lipoproteins primarily through scavenger receptors such as CD36 and SRA. Negative regulation of foam cell differentiation often involves downregulation of these receptors. For example, RFX1 has been shown to regulate CD36 expression, and its modulation affects foam cell formation. Similarly, inhibition of NFAT suppresses foam cell formation, partly by reducing scavenger receptor expression. The nuclear receptor PPARγ can also influence scavenger receptor expression, although its role is complex and context-dependent.
Promotion of Cholesterol Efflux
In simple terms: This step helps macrophages pump out excess cholesterol.
Cholesterol efflux is mediated by transporters such as ABCA1 and ABCG1, which transfer cholesterol to extracellular acceptors like HDL. Negative regulators of foam cell differentiation can enhance efflux pathways. For instance, omentin-1 has been shown to counteract atherogenesis, potentially by promoting cholesterol efflux. PPARγ and PPARα activation also upregulates ABCA1 and ABCG1, facilitating cholesterol removal.
Modulation of Inflammatory Signaling
In simple terms: This step reduces inflammation that drives foam cell formation.
Inflammation promotes foam cell formation by increasing scavenger receptor expression and lipid uptake. Negative regulators often suppress pro-inflammatory pathways. CNP (C-type natriuretic peptide) ameliorates macrophage inflammatory response and atherosclerosis, indicating its role in negative regulation. Inhibition of NFAT also reduces inflammatory cytokine production and foam cell formation. PPARγ activation exerts anti-inflammatory effects in macrophages, contributing to its anti-atherogenic actions.
Transcriptional and Post-Transcriptional Control
In simple terms: This step controls the production of proteins involved in foam cell formation.
Transcription factors such as KLF4 and RFX1 regulate the expression of genes involved in lipid uptake and efflux. KLF4 interacts with SRA and modulates its activity, affecting foam cell formation. RFX1 regulates CD36 expression at the transcriptional level. Additionally, post-transcriptional mechanisms, including microRNAs and RNA-binding proteins, can influence the stability of mRNAs encoding these proteins, though specific examples in this context are still emerging.
Cross-Talk with Metabolic Pathways
In simple terms: This step links foam cell regulation to overall metabolism.
Negative regulation of foam cell differentiation is intertwined with systemic metabolism. PPARs are sensors of lipid metabolites and regulate energy homeostasis. Omentin-1, an adipokine, links adipose tissue function to vascular health. CNP is a natriuretic peptide with metabolic effects. Thus, metabolic disorders such as diabetes and obesity can impair negative regulation, exacerbating foam cell formation.
Key Genes Involved in GO:0010745 negative regulation of macrophage derived foam cell differentiation
The following genes and proteins have been experimentally implicated in the negative regulation of macrophage derived foam cell differentiation, based on the provided literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPARG | Nuclear receptor that promotes cholesterol efflux and inhibits inflammation | Target of thiazolidinediones; modulates foam cell formation |
| PPARA | Nuclear receptor that enhances fatty acid oxidation and cholesterol efflux | Target of fibrates; anti-atherogenic effects |
| KLF4 | Transcription factor that interacts with SRA and regulates foam cell formation | Modulated by formononetin; potential therapeutic target |
| RFX1 | Transcription factor that regulates CD36 expression | Regulates foam cell formation and atherosclerosis |
| CNP | C-type natriuretic peptide that reduces macrophage inflammation | Ameliorates atherosclerosis in animal models |
| OMENTIN-1 | Adipokine that counteracts atherogenesis | Potential biomarker and therapeutic |
| NFAT | Transcription factor family; inhibition suppresses foam cell formation | Target for anti-atherosclerotic therapy |
| CD36 | Scavenger receptor for oxidized LDL; target of negative regulation | Key player in foam cell formation |
| SRA | Scavenger receptor for modified LDL; regulated by KLF4 | Mediates lipid uptake |
| ABCA1 | Cholesterol efflux transporter; upregulated by PPARs | Promotes cholesterol removal |
| ABCG1 | Cholesterol efflux transporter; upregulated by PPARs | Promotes cholesterol removal |
| COX2 | Cyclooxygenase-2; feedback regulated by PPARγ | Involved in inflammation resolution |
| IL-6 | Pro-inflammatory cytokine; suppressed by negative regulators | Marker of inflammation |
| TNF | Pro-inflammatory cytokine; suppressed by negative regulators | Marker of inflammation |
| MCP-1 | Chemokine that recruits monocytes; modulated by negative regulators | Involved in plaque progression |
| MMP9 | Matrix metalloproteinase; associated with plaque instability | Potential downstream effector |
| GPR37 | Orphan G protein-coupled receptor; potential role in foam cells | Identified in bioinformatics analysis |
How Is negative regulation of macrophage derived foam cell differentiation Regulated?
The negative regulation of macrophage derived foam cell differentiation is controlled by a complex network of signaling pathways and transcription factors. Nuclear receptors PPARγ and PPARα play central roles by sensing lipid metabolites and regulating gene expression programs that promote cholesterol efflux and inhibit inflammation. Inflammatory signaling pathways, such as NF-κB and NFAT, are often suppressed by negative regulators to limit foam cell formation. Additionally, secreted factors like CNP and omentin-1 can act in a paracrine or endocrine manner to modulate macrophage function. The interplay between these pathways ensures a balance between lipid uptake and efflux, and disruption of this balance leads to pathological foam cell accumulation.
negative regulation of macrophage derived foam cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARG | Atherosclerosis, diabetes | ApoE-/- mice with PPARγ overexpression or knockout |
| KLF4 | Atherosclerosis | LDLR-/- mice with macrophage-specific KLF4 knockout |
| RFX1 | Atherosclerosis | ApoE-/- mice with RFX1 knockdown |
| CNP | Atherosclerosis | ApoE-/- mice treated with CNP |
| OMENTIN-1 | Atherosclerosis, obesity | ApoE-/- mice with omentin-1 overexpression |
Atherosclerosis and Cardiovascular Disease
Atherosclerosis is the primary disease linked to dysregulated foam cell formation. Negative regulators of this process are protective against plaque development. For instance, CNP ameliorates atherosclerosis by reducing macrophage inflammation. Inhibition of NFAT suppresses foam cell formation and diet-induced atherosclerosis. RFX1 regulates CD36 and affects atherosclerosis progression. Omentin-1 counteracts atherogenesis. Formononetin attenuates atherosclerosis via KLF4 and SRA. Thus, targeting these pathways holds therapeutic promise.
Metabolic Disorders
Metabolic disorders such as diabetes and obesity are associated with increased foam cell formation and cardiovascular risk. PPARγ and PPARα are key regulators of lipid and glucose metabolism, and their activation improves metabolic parameters while also inhibiting foam cell formation. Omentin-1, an adipokine, links obesity to vascular disease. Therefore, negative regulation of foam cell differentiation is intertwined with systemic metabolism.
Inflammation and Immune Regulation
Chronic inflammation contributes to foam cell formation. Negative regulators often exert anti-inflammatory effects. For example, CNP reduces macrophage inflammatory response, and NFAT inhibition suppresses inflammatory cytokine production. PPARγ activation also has anti-inflammatory actions. Thus, the negative regulation of foam cell differentiation is part of a broader anti-inflammatory program in macrophages.
From negative regulation of macrophage derived foam cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate foam cell formation? | CRISPR knockout of gene X in macrophages followed by oxLDL treatment |
| Does a specific point mutation in gene X affect its function? | CRISPR point mutation knock-in in cell lines or primary macrophages |
| Does overexpression of gene X reduce foam cell formation? | Lentiviral overexpression of gene X in macrophages |
| Does gene X interact with protein Y? | Knock-in of tagged gene X for co-immunoprecipitation |
| Is gene X required for the anti-atherogenic effect of drug Z? | Macrophage-specific knockout of gene X in ApoE-/- mice treated with drug Z |
| Can gene X be targeted for therapy? | In vivo CRISPR delivery to macrophages in mouse models |
How to Study the negative regulation of macrophage derived foam cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Oil Red O staining | Neutral lipid accumulation | Quantification of foam cell formation in vitro |
| Filipin staining | Free cholesterol | Visualization of cholesterol crystals |
| qRT-PCR | mRNA expression levels | Assessment of scavenger receptors and efflux transporters |
| Western blot | Protein expression and modification | Validation of gene knockout or overexpression |
| RNA-seq | Global transcriptome changes | Identification of pathways regulated by candidate genes |
| CRISPR screen | Genes affecting foam cell formation | Discovery of novel negative regulators |
| Aortic root histology | Atherosclerotic plaque size and composition | In vivo validation in mouse models |
Lipid Uptake and Foam Cell Formation Assays
To study negative regulation of foam cell differentiation, researchers commonly use oxidized LDL (oxLDL) or acetylated LDL (acLDL) to induce foam cell formation in macrophages. Lipid accumulation is quantified using Oil Red O staining, filipin staining for free cholesterol, or high-performance liquid chromatography (HPLC) for cholesterol esters. These assays are fundamental for assessing the impact of genetic manipulations.
Gene Expression Analysis
Quantitative RT-PCR and RNA-seq are used to measure mRNA levels of scavenger receptors (CD36, SRA), cholesterol efflux transporters (ABCA1, ABCG1), and inflammatory cytokines. Western blotting and immunofluorescence can assess protein levels and localization. These methods help elucidate the molecular mechanisms by which negative regulators act.
CRISPR-Based Genetic Screens
Pooled CRISPR knockout screens can identify novel negative regulators of foam cell formation. Macrophages are transduced with a lentiviral sgRNA library, treated with oxLDL, and sorted based on lipid content. Enriched sgRNAs point to genes whose loss increases foam cell formation, revealing potential negative regulators. This unbiased approach can uncover new therapeutic targets.
In Vivo Atherosclerosis Models
ApoE-/- and LDLR-/- mice are standard models for atherosclerosis. Macrophage-specific gene manipulation using bone marrow transplantation or CRISPR-mediated gene editing can test the role of candidate genes in plaque formation. Lesion size is assessed by aortic root histology or en face staining. These models provide physiological relevance.
How CRISPR Can Be Used to Study GO:0010745 negative regulation of macrophage derived foam cell differentiation
Knockout
CRISPR knockout of candidate negative regulators in macrophage cell lines (e.g., RAW264.7, THP-1) or primary macrophages can determine whether the gene is required to suppress foam cell formation. For example, knockout of RFX1 or NFAT components would be expected to increase foam cell formation upon oxLDL treatment. This approach provides causal evidence.
Point Mutation
Point mutations can be introduced to mimic human genetic variants or to abrogate specific post-translational modifications. For instance, mutating phosphorylation sites in KLF4 or PPARγ could reveal their functional significance in foam cell regulation. CRISPR base editing or prime editing enables precise point mutations without double-strand breaks.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP, HA) allows for visualization and immunoprecipitation. Knock-in of reporter genes under the control of endogenous promoters can monitor gene expression dynamics. For example, a CD36-GFP knock-in would enable tracking of CD36 expression during foam cell formation. This approach is valuable for mechanistic studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to increase the expression of candidate negative regulators. Overexpression of CNP or omentin-1 in macrophages would be expected to reduce foam cell formation. This gain-of-function approach complements knockout studies.
How EDITGENE Supports negative regulation of macrophage derived foam cell differentiation Research
Researchers studying negative regulation of macrophage derived foam cell differentiation-related genes often need to determine whether a candidate gene is causally involved in suppressing foam cell formation. This requires precise genetic manipulation in relevant cell models, followed by functional assays. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such research, from gene knockout to knock-in and overexpression, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of macrophage derived foam cell differentiation research.
Frequently Asked Questions About negative regulation of macrophage derived foam cell differentiation
What is GO:0010745?
GO:0010745 is a Gene Ontology term for the biological process 'negative regulation of macrophage derived foam cell differentiation'. It encompasses any process that suppresses the conversion of macrophages into lipid-laden foam cells.
What genes are involved in negative regulation of macrophage derived foam cell differentiation?
Key genes include PPARG, PPARA, KLF4, RFX1, CNP, OMENTIN-1, and NFAT, among others. These genes encode transcription factors, nuclear receptors, and secreted proteins that inhibit foam cell formation.
How does PPARγ negatively regulate foam cell formation?
PPARγ promotes cholesterol efflux by upregulating ABCA1 and ABCG1, and it exerts anti-inflammatory effects, thereby inhibiting foam cell formation.
What is the role of KLF4 in foam cell differentiation?
KLF4 is a transcription factor that interacts with scavenger receptor SRA and modulates its activity. Formononetin attenuates atherosclerosis by regulating the interaction between KLF4 and SRA.
Can CRISPR be used to study negative regulation of foam cell differentiation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes in this process.
What are common experimental models for studying foam cell formation?
Common models include oxLDL-treated macrophage cell lines (THP-1, RAW264.7), primary macrophages, and in vivo models such as ApoE-/- and LDLR-/- mice.
How is foam cell formation quantified?
Foam cell formation is typically quantified by Oil Red O staining, filipin staining, or HPLC measurement of cholesterol esters.
What diseases are associated with dysregulated foam cell differentiation?
Atherosclerosis and cardiovascular disease are the primary diseases. Metabolic disorders and chronic inflammation are also linked.
What is the role of CNP in atherosclerosis?
CNP (C-type natriuretic peptide) ameliorates macrophage inflammatory response and atherosclerosis, acting as a negative regulator of foam cell formation.
How does omentin-1 counteract atherogenesis?
Omentin-1, an adipokine, has counteractive effects against atherogenesis, potentially by promoting cholesterol efflux and reducing inflammation.
Conclusion
The negative regulation of macrophage derived foam cell differentiation (GO:0010745) is a critical biological process that protects against atherosclerosis. Key regulators such as PPARγ, KLF4, RFX1, CNP, and omentin-1 have been identified through molecular and genetic studies. Understanding these mechanisms offers opportunities for therapeutic intervention. CRISPR-based models are indispensable for dissecting the causal roles of these genes and for discovering new targets. EDITGENE provides comprehensive services to support such research, from knockout to overexpression and library screening.
References
- 1. Bao Q et al.. 2024. CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis.. Circ Res 134(8):e72-e91 PMID: 38456298
- 2. Du M et al.. 2021. Inhibition of NFAT suppresses foam cell formation and the development of diet-induced atherosclerosis.. FASEB J 35(10):e21951 PMID: 34551141
- 3. Yang S et al.. 2024. RFX1 regulates foam cell formation and atherosclerosis by mediating CD36 expression.. Int Immunopharmacol 130:111751 PMID: 38402833
- 4. Liang K et al.. 2023. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis.. Aging (Albany NY) 15(19):10146-10167 PMID: 37837549
- 5. Neve BP et al.. 2000. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.. Biochem Pharmacol 60(8):1245-50 PMID: 11007963
- 6. Watanabe K et al.. 2016. Counteractive effects of omentin-1 against atherogenesis†.. Cardiovasc Res 110(1):118-28 PMID: 26790473
- 7. Ma C et al.. 2020. Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE(-/-) mice.. Theranostics 10(3):1090-1106 PMID: 31938053
- 8. Inoue H et al.. 2000. Feedback control of cyclooxygenase-2 expression through PPARgamma.. J Biol Chem 275(36):28028-32 PMID: 10827178
